Obesity and the lung: 5 · Obesity and COPD

Thorax

Volumn 63, Issue 12, 2008, Pages 1110-1117

  Franssen, F M E ^a   O'Donnell, D E ^b   Goossens, G H ^c   Blaak, E E ^c   Schols, A M W J ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b QUEEN S UNIVERSITY   (Canada)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; BODY FAT; CHRONIC OBSTRUCTIVE LUNG DISEASE; EXERCISE; HUMAN; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LUNG FUNCTION; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 57149096723     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2007.086827     Document Type: Article

References (128)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
2. World Health Organization. Overweight and obesity: a new nutrition emergency? Monitoring the rapidly emerging public health problem of overweight and obesity: the WHO global database on body mass index. SCN News 2004:5-12.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504
5. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 2000.
6. Jubber AS. Respiratory complications of obesity, Int J Clin Pract 2004;58:573-80.
7. Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol 2005;115:925-7.
8. Poulain M, Doucet M, Major GC, et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006;174:1293-9.
9. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972-7.
10. Dallman MF, la Fleur SE, Pecoraro NC, et al. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004;145:2633-8.
11. Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006;15:84-91.
12. Schokker DF, Visscher TL, Nooyens AC, et al. Prevalence of overweight and obesity in the Netherlands. Obes Rev 2007;8:101-8.
13. Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. Respir Res 2007;8:7.
14. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25:226-34.
15. Filley GF, Beckwitt HJ, Reeves JT, et al. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med 1968;44:26-38.
16. Guerra S, Sherrill DL, Bobadilla A, et al. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 2002;122:1256-63.
17. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-6.
18. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006;173:79-83.
19. Engelen MP, Schols AM, Lamers RJ, et al. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999;18:275-80.
20. Roubenoff R. The pathophysiology of wasting in the elderly. J Nutr 1999;129:256-95.
21. Collins LC, Hoberty PD, Walker JF, et al. The effect of body fat distribution on pulmonary function tests. Chest 1995;107:1298-302.
22. Lazarus R, Sparrow D, Weiss ST. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest 1997;111:891-8.
23. Naimark A, Cherniack RM. Compliance of the respiratory system and its components in health and obesity. J Appl Physiol 1960;15:377- 82.
24. Sharp JT, Henry JP, Sweany SK, et al. The total work of breathing in normal and obese men. J Cli Invest 1964;43:728-39.
25. Suratt PM, Wilhoit SC, Hsiao HS, et al. Compliance of chest wall in obese subjects. J Appl Physiol 1984;57:403-7.
26. Ray CS, Sue DY, Bray G, et al. Effects of obesity on respiratory function. Am Rev Respir Dis 1983;128:501-6.
27. Ofir D, Laveneziana P, Webb KA, et al. Ventilatory and perceptual responses to cycle exercise in obese women. J Appl Physiol 2007;102:2217-26.
28. Ferretti A, Giampiccolo P, Cavalli A, et al. Expiratory flow limitation and orthopnea in massively obese subjects. Chest 2001;119:1401-8.
29. Rubinstein I, Zamel N, DuBarry L, et al. Airflow limitation in morbidly obese, nonsmoking men. Ann Intern Med 1990;112:828- 32.
30. Zerah F, Harf A, Perlemuter L, et al. Effects of obesity on respiratory resistance. Chest 1993;103:1470-6.
31. Thomas PS, Cowen ER, Hulands G, et al. Respiratory function in the morbidly obese before and after weight loss. Thorax 1989;44:382-6.
32. Holley HS, Milic-Emili J, Becklake MR, et al. Regional distribution of pulmonary ventilation and perfusion in obesity. J Clin Invest 1967;46:475-81.
33. Sampson MG, Grassino K. Neuromechanical properties in obese patients during carbon dioxide rebreathing. Am J Med 1983;75:81- 90.
34. Gilbert R, Sipple JH, Auchincloss JH Jr. Respiratory control and work of breathing in obese subjects. J Appl Physiol 1961;16:21-6.
35. Kelly TM, Jensen RL, Elliott CG, et al. Maximum respiratory pressures in morbidly obese subjects. Respiration 1988;54:73-7.
36. Dempsey JA, Reddan W, Balke B, et al. Work capacity determinants and physiologic cost of weight-supported work in obesity. J Appl Physiol 1966;21:1815-20.
37. Whipp BJ, Davis JA. The ventilatory stress of exercise in obesity. Am Rev Respir Dis 1984;129:590-2.
38. Babb TG, Buskirk ER, Hodgson JL. Exercise end-expiratory lung volumes in lean and moderately obese women, Int J Obes 1989;13:11-9.
39. Babb TG, Korzick D, Meador M, et al. Ventilatory response of moderately obese women to submaximal exercise. Int J Obes 1991;15:59-65.
40. Chlif M, Keochkerian D, Feki Y, et al. Inspiratory muscle activity during incremental exercise in obese men. Int J Obes (Lond) 2007;31:1456-63.
41. Li J, Li S, Fevers RJ, et al. Influence of body fat distribution on oxygen uptake and pulmonary performance in morbidly obese females during exercise. Respirology 2001;6:9-13.
42. Kress JP, Pohlman AS, Alverdy J, et al. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med 1999;160:883-6.
43. Lennmarken C, Sandstedt S, von Schenck H, et al. Skeletal muscle function and metabolism in obese women. JPEN J Perenter Enteral Nutr 1986;10:583-7.
44. Alpert MA, Lambert CR. Terry BE, et al. Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes Relat Metab Disord 1995;19:550-7.
45. Swinburn CR, Cooper BG, Mould H, et al. Adverse effect of additional weight on exercise against gravity in patients with chronic obstructive airways disease. Thorax 1989;44:716-20.
46. Gibson GJ. Obesity, respiratory function and breathlessness. Thorax 2000;55(Suppl 1):S41-4.
47. O'Donnell DE, Ofir D, Laveneziana P. Patterns of cardiopulmonary response to exercise in lung diseases. Eur Respir Monogr 2006;40:69-92.
48. O'Donnell DE, Voduc N. Mechanisms of dyspnea in restrictive lung disorders. 2nd ed. Boca Raton, FL: Taylor & Francis Group, 2005:87-114.
49. O'Donnell DE, Hamilton AL Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 2006;101:1025-35.
50. Engelen MP, Schols AM, Does JD, et al. Skeletal muscle weakness is associated with wasting of extremity fat- free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2000;71:733-8.
51. Baarends EM, Schols AM, Mostert R, et al. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2807-13.
52. Visser M, Langlois J, Guralnik JM, et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr 1998;68:584-90.
53. Sternfeld B, Ngo L, Satariano WA, et al. Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am J Epidemiol 2002;156:110- 21.
54. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-9.
55. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-61.
56. Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989;139:1435-8.
57. Chailleux E, Laaban JP, Veale O. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003;123:1460-6.
58. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32.
59. Kalantar-Zadeh K, Norwich TB, Oreopoulos A, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007;10:433-42.
60. Watson L, Vonk JM, Lofdahl CG, et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 2006;100:746-53.
61. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-64.
62. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-6.
63. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
64. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-9.
65. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
66. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
67. Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance and inflammation: a further systemic complication of COPD. COPD 2007;4:121-6.
68. Koehler F, Doehner W, Hoernig S, et al. Anorexia in chronic obstructive pulmonary disease: association to cachexia and hormonal derangement. Int J Cardiol 2007;119:83-9.
69. Jakobsson P, Jorfeldt L. Oxygen supplementation increases glucose tolerance during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with severe COPD and chronic hypoxaemia. Clin Physiol Funct Imaging 2006;26:271-4.
70. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
71. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-18.
72. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001;60:375-50.
73. Forouhi NG, Jenkinson G, Thomas EL, et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 1999;42:932-5.
74. Koyama K, Chen G, Lee Y, et al. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997;273:E708-13.
75. Bjorntorp P. Liver triglycerides and metabolism. Int J Obes Relat Metab Disord 1995;19:839-40.
76. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
77. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
78. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27(Suppl 3):S25-8.
79. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-90.
80. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001;7:1138-43.
81. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4.
82. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
83. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.
84. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
85. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
86. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
87. Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL6 levels in obese women. Int J Obes Relat Metab Disord 2004;28:993-7.
88. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
89. 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000;49:1374-80.
90. Klein S, Coppack SW, Mohamed-Ali V, et al. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996;45:984-7.
91. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
92. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
93. Skurk T, Alberti-Huber C, Herder C, et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92:1023-33.
94. Waisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
95. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
96. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006;341:507-14.
97. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007;56:901-11.
98. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005;54:2277-86.
99. Blaak EE, van Baak MA, Kemerink GJ, et al. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995;44:183-7.
100. Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996;91:679-83.
101. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55.
102. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-12.
103. 2-regulated gene expression. Faseb J 2002;16:1151-62.
104. Chen B, Lam KS, Wang Y, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006;341:549-56.
105. Segawa K, Fukuhara A, Hosogai N, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1 alpha-dependent mechanism. Biochem Biophys Res Commun 2006;349:875-82.
106. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007;455:479-92.
107. Ye J, Gao Z, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007;293:E1118-28.
108. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009- 14.
109. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-55.
110. Yun Z, Maecker HL, Johnson RS, et al. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002;2:331-41.
111. Weyer C, Foley JE, Bogardus C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000;43:1498-506.
112. Bi M, Naczki C, Koritzinsky M, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005;24:3470-81.
113. Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 2005;3:597-605.
114. Carriere A, Carmona MC, Fernandez Y, et al. Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect. J Biol Chem 2004;279:40462-9.
115. Nakatani Y, Kaneto H, Kawamori D, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005;280:847-51.
116. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999;48:1113-9.
117. Gosker H, Zeegers M, Wouters E, et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007;62:944-9.
118. American Thoracic Society/European Respiratory Society Statement. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:51-40.
119. Jakobsson P, Jorfeldt L, von Schenck H. Fat metabolism and its response to infusion of insulin and glucose in patients with advanced chronic obstructive pulmonary disease. Clin Physiol 1995;15:319-29.
120. Schiffelers SL, Blaak EE, Baarends EM, et al. β-Adrenoceptor-mediated thermogenesis and lipolysis in patients with chronic obstructive pulmonary disease. Am J Physiol Endocrinol Metab 2001;280:E357-64.
121. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
122. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-24.
123. Petersen AM, Penkowa M, Iversen M, et al. Elevated levels of IL18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 2007;185:161-71.
124. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22.
125. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1414-8.
126. Goossens GH, Jocken JWE, van Baak MA, et al. Short-term beta-adrenergic regulation of leptin, adiponectin and ILB secretion in vivo in lean and obese subjects. Diabetes Obes Metab 22 Apr 2008 [Epub ahead of print].
127. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-3.
128. Hjalmarsen A, Aasebo U, Birkeland K, et al. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996;22:37-42.